Moreover, a decrease in cholinesterase activity may, to some extent, disrupt the amyloid-beta (Aβ) aggregation, a hallmark peptide of AD [5], also making causative treatment of the disease potentially possible. This evidence concerns the gene BCHE and Alzheimer disease.